J Pain Palliat Care Pharmacother. 2022 Jun;36(2):103-111. doi: 10.1080/15360288.2022.2070691. Epub 2022 Jun 1.
The objective of this study is to assess the differences in buprenorphine prescribers from a county level in the state of Texas by comparing the Substance Abuse and Mental Health Services Administration (SAMHSA) Buprenorphine Practitioner Locator to the Drug Enforcement Administration's (DEA) Controlled Substance Act (CSA) database.
County-level counts of buprenorphine prescribers were calculated from both the publicly available SAMHSA buprenorphine practitioner locator list and the DEA CSA database. These were then used to estimate the number of providers per 100,000 residents in each county. Regional variation in access to buprenorphine was compared descriptively across the state using poverty data from the US Census and county-level demography from the Texas Demographic Center.
This study found 68.8% more X-waivered providers on the DEA CSA database (n = 2,622) with at least one provider reported in 125 of 144 counties in the state (49.2%) compared to the SAMHSA Buprenorphine Practitioner Locator (n = 1,553) with at least one provider reported in 103 counties (40.5%).
The lack of a complete public registry of buprenorphine prescribers can inhibit the ability of patients to identify a convenient treatment. More work is needed to quantify the gap between treatment capacity and treatment need.
本研究旨在通过比较物质滥用和心理健康服务管理局（SAMHSA）的丁丙诺啡从业者定位器与毒品执法局（DEA）的《受控物质法》（CSA）数据库，评估德克萨斯州县级丁丙诺啡处方者之间的差异。
从 SAMHSA 公开的丁丙诺啡从业者定位器列表和 DEA CSA 数据库中计算了县级丁丙诺啡处方者的计数。然后，使用这些计数来估计每个县每 10 万居民中的提供者人数。使用美国人口普查的贫困数据和德克萨斯州人口中心的县级人口统计学数据，对全州范围内丁丙诺啡获取的区域差异进行了描述性比较。
本研究发现，与 SAMHSA 丁丙诺啡从业者定位器（n=1553）相比，在州内 144 个县中的 103 个县（40.5%）至少有一名报告者相比，DEA CSA 数据库（n=2622）中有 X 豁免的提供者多 68.8%，至少有一名报告者的县有 125 个（49.2%）。
缺乏完整的丁丙诺啡处方者公共登记册可能会阻碍患者识别便利的治疗方法。需要做更多的工作来量化治疗能力和治疗需求之间的差距。
